Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients.

Although there were no statistically significant differences between groups, administration of the higher dose of bone marrow mononuclear cells consistently showed a trend toward enhanced neurologic recovery ( Fig. 3f–i ).

also in 53,322 other papers